<DOC>
	<DOCNO>NCT02485353</DOCNO>
	<brief_summary>This pilot efficacy assessment clinical trial vosaroxin cytarabine treatment adult 60 year age old previously untreated acute myeloid leukemia . A total 17 evaluable patient plan treat study .</brief_summary>
	<brief_title>Study Vosaroxin Cytarabine Treatment Adults 60 Years Age Older With Previously Untreated AML</brief_title>
	<detailed_description>Primary objective : rate complete remission ( morphologic complete remission morphologic complete remission incomplete blood count recovery ) Secondary objective : ( 1 ) safety combination induction therapy old patient previously unexposed intensive chemotherapy ; ( 2 ) progression-free survival ; ( 3 ) length stay hospital induction ; ( 4 ) 30- 60-day mortality rate . The treatment period include 4 cycle treatment ( induction 1 , induction 2 , consolidation 1 , consolidation 2 ) . In cycle , first day study treatment consider day 1 . - Each cycle include vosaroxin treatment day 1 4 ( total 2 day ) cytarabine treatment day 1-5 ( total 5 day ) follow variable interval require achieve hematologic recovery , define absolute neutrophil count ( ANC ) &gt; 1000 cells/L . - Up 2 cycle consolidation treatment may complete eligible patient remission ( morphologic complete remission morphologic complete remission incomplete blood count recovery ) safety parameter meet .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Age &gt; 60 year A diagnosis AML base WHO classification ( &gt; 20 % myeloblast peripheral blood bone marrow ) No previous treatment chemotherapy AML , hydroxyurea . Previous treatment hypomethylating agent acceptable Patients must ECOG ( Zubrod ) performance status 02 ( see Appendix I ) . Patients must adequate hepatic function total bilirubin &lt; 1.5 time upper limit normal ( ULN ) case Gilbert disease , ALT AST &lt; 2.5 time ULN ; adequate renal function define serum creatinine &lt; 2 time ULN . Clinically significant nonhematologic toxicity prior therapy recover grade 1 per Common Terminology Criteria Adverse Events ( CTCAE ) version 4.03 new Patients must ability understand willingness sign write informed consent . A sign informed consent must obtain prior initiation treatment Left ventricular ejection fraction ( LVEF ) least 40 % multiple gated acquisition ( MUGA ) scan echocardiogram ( ECHO ) Patients known central nervous system ( CNS ) leukemia spinal fluid cytology , flow cytometry image . A lumbar puncture require unless CNS involvement clinically suspect . Patients sign symptom leukemic meningitis history leukemic meningitis must negative lumbar puncture within 2 week study enrollment . A diagnosis acute promyelocytic leukemia ( APL ) . The study require rule APL every subject . However , clinical suspicion APL , diagnosis rule initiation treatment . Active malignancy currently undergo chemo radiation therapy . Hormone therapy acceptable . Active serious infection discretion treat physician make patient ineligible chemotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Vosaroxin</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Remission Induction</keyword>
	<keyword>Safety</keyword>
	<keyword>Progression-Free Survival</keyword>
	<keyword>Mortality Rate</keyword>
	<keyword>Length Stay</keyword>
</DOC>